ClinicalTrials.gov
ClinicalTrials.gov Menu

Fractalkine, a CX3C Chemokine, Act as a Mediator of Ocular Angiogenesis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00728598
Recruitment Status : Completed
First Posted : August 6, 2008
Last Update Posted : August 6, 2008
Sponsor:
Information provided by:
National Taiwan University Hospital

Brief Summary:
Fractalkine (FKN) is a chemoattractant and adhesion molecule for leukocytes. Angiogenic effect of FKN also has been reported. We investigate FKN-mediated angiogenesis in ocular angiogenic disorders.

Condition or disease
Proliferative Diabetic Retinopathy Angiogenesis

Detailed Description:
Fractalkine (FKN), the sole member of the CX3C chemokine family, is named for its fractal geometry. The CX3C motif, with three amino acids between the two terminal cysteines, makes fractalkine distinct from other chemokines.The structure of fractalkine, a membrane-bound glycoprotein with the chemokines domain atop an extended mucin-like stalk, also is unique.Membrane-bound FKN can be markedly induced on primary endothelial cells by inflammatory cytokines; this form promotes the robust adhesion of monocytes and T lymphocytes. Soluble FKN can be released by proteolysis at an efficient chemotactic activity level for monocytes and T cells. Thus, FKN is a versatile molecule regulating both cell-cell interactions in its membrane-bound form and directed-cell migration in its soluble form. The receptor of FKN, CXC3R1, is a G protein-couple protein, which expresses T lymphocytes, monocytes, natural killer (NK) cells, microglia, and neurons.Sulfation of tyrosine enhances the function of CX3CR1 in cell capture and firm adhesion. Fractalkine is expressed constitutively in the kidney, heart, lung, and brain. Fractalkine has demonstrated an important role in CNS inflammation, cardiac allograft rejection, arteriogenesis, renal disease, psoriasis, and during pregnancy. Silverman et al demonstrated the presence of FKN in normal cultured microvascular endothelial and stromal cells of iris and retina in vitro. Upon inflammatory cytokine stimulation, EC also express FKN and its receptors with FKN secretion in an autocrine manner. In addition to EC chemotaxis and tube formation, FKN is an angiogenic mediator in rheumatoid arthritis. Therefore, we hypothesize that FKN not only participates in ocular inflammatory reactions, but also plays an important role in ocular angiogenesis.

Study Type : Observational
Actual Enrollment : 30 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Vitreous Levels of Patients With Proliferative Diabetic Retinopathy.
Study Start Date : January 1998
Actual Primary Completion Date : December 1998
Actual Study Completion Date : December 1998

Resource links provided by the National Library of Medicine


Group/Cohort
1
Proliferative diabetic retinopathy, active.
2
Proliferative diabetic retinopathy, quiescent.
3
Control group. Patients with macular hole or idiopathic epiretinal membrane receiving vitrectomy for their disease.



Primary Outcome Measures :
  1. Vitreous levels and serum levels of Fractalkine, VEGF, other growth factor. [ Time Frame: vitreous sample collected on vitrectomy ]

Biospecimen Retention:   Samples Without DNA
Vitreous sample and blood sample


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with proliferative diabetic retinopathy, who will receive vitrectomy.
Criteria

Inclusion Criteria:

  • clinical diagnosis of proliferative diabetic retinopathy.
  • who will receive vitrectomy for treatment of disease.

Exclusion Criteria:

  • previous ocular surgical history.
  • history of uveitis
  • history of ocular trauma.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00728598


Locations
Taiwan
The department of ophthalmology, National Taiwan University Hospital
Taipei, Taiwan
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Principal Investigator: Chang-Hao Yang, MD, PhD Ophthalmology, National Taiwan University Hospital

Publications:
ClinicalTrials.gov Identifier: NCT00728598     History of Changes
Other Study ID Numbers: 9561702008
First Posted: August 6, 2008    Key Record Dates
Last Update Posted: August 6, 2008
Last Verified: August 2008

Keywords provided by National Taiwan University Hospital:
Proliferative diabetic retinopathy
Angiogenesis
Vitreous levels
Vascular endothelial growth factor
Fractalkine
Growth factor

Additional relevant MeSH terms:
Retinal Diseases
Diabetic Retinopathy
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases